There is no current therapy for Fragile X syndrome, a form of autism caused by a genetic mutation. But that could soon change. Researchers across the country, including Raphael Bernier, PhD, are launching a clinical trial looking at how a topical cannabidiol (CBD) gel can reduce the symptoms of this genetic disorder.